CRSP
CRISPR Therapeutics AG
Next earnings Aug 3, 2026 · consensus $-1.23 EPS, $6.69M rev
Last earnings +3.8% on 2026-05-04
$53.55
▼ -0.81%$53.55▲ +20.53%
over 1Y
L $44.25EODHDH $76.78
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.8%
1W+0.9%
1M+3.8%
3M+13.7%
YTD-0.4%
1Y+20.5%
Hold
Conviction
Horizon
Long (>12mo)
Street · 32 analysts
Buy
Well-funded clinical-stage gene-editing biotech — minimal revenue and heavy R&D burn, with value resting on pipeline catalysts, not financials.
CRISPR Therapeutics is a gene-editing pioneer whose value is driven by its pipeline and its approved therapy Casgevy (partnered with Vertex), not by its income statement. The financials are those of a clinical-stage biotech: FY2025 revenue was just $3.51M (collaboration revenue is lumpy and fell 90.6%), against an operating loss of -$665M and a net loss of -$582M as the company invests $285M in R&D. The percentage 'margins' (-16,569.8% net) and the 1479.2x P/S are mathematical artifacts of near-zero revenue and carry no analytical meaning here.
Sources: SEC EDGAR (CIK 0001674416, latest 10-Q filed 2026-05-04) · EODHD · analysis by claude-code · as of 6/21/2026, 8:57:19 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.